Testing a new medication for fatty liver disease with moderate scarring

Plain-English translation of NCT07221227 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a medication called to see if it can help people with a condition called metabolic dysfunction-associated steatohepatitis (MASH)—a type of fatty liver disease that also involves inflammation and scarring. Researchers want to know if this medication can reduce liver inflammation, improve scarring, and help people's livers function better. About 1,200 people will participate, and each person will randomly receive either the medication at one of two doses or a placebo (inactive treatment).

MASH is a serious liver condition affecting millions of people, and currently there are limited treatment options. This medication is being tested because early research suggests it may help reduce liver damage and inflammation in ways that existing treatments cannot.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old at the time you enroll
you have been diagnosed with metabolic dysfunction-associated fatty liver disease with confirmed scarring (stage F2 or F3) based on a liver biopsy
you have at least two features of metabolic syndrome (such as high blood pressure, high blood sugar, or obesity)
you are able to understand and sign an informed consent form before the study begins

You likely don't qualify if…

you have certain blood test results that indicate severe liver disease (very high liver enzymes, low blood protein, or kidney problems)
you have active infection with HIV, hepatitis B, or hepatitis C
you have cirrhosis (advanced scarring of the liver) or signs of liver failure such as fluid buildup in the abdomen or internal bleeding
you have had excessive alcohol use in the past year, or if you cannot have a liver biopsy for medical reasons
you have other serious chronic liver diseases from causes other than metabolic dysfunction

What participation looks like

If you join this study, you will be randomly assigned to receive either the new medication (at one of two dose levels) or a placebo, taken on a regular schedule. You will need to have a liver biopsy before starting the study to confirm your diagnosis. Throughout the trial, you'll attend multiple visits for blood tests, physical exams, and check-ins to monitor how the treatment is working and watch for any side effects. The study will follow you over several months to see whether the medication helps reduce liver inflammation and scarring compared to placebo.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(49 sites)

United States

GSK Investigational Site, Arcadia, California

GSK Investigational Site, Covina, California

GSK Investigational Site, Los Angeles, California

GSK Investigational Site, Santa Maria, California

GSK Investigational Site, Van Nuys, California